Kangchen Pharma

Company Profile
Kangchen Pharmaceutical (Stock Code: 603590), founded in 2003, adhering to the core mission of "safeguarding human health with life sciences," insists on innovative drug R&D and emphasizes product novelty and specialty, becoming a Chinese high-tech pharmaceutical enterprise integrating R&D, production, and marketing. The company is located in Beijing Zhongguancun Life Science Park, with an independent spacious office building and a research building of nearly 5,000 square meters, and also has a 110,000 square meter international standardized high-tech pharmaceutical production base in Zhongguancun Miyun Park, Beijing.
Product Introduction
The company currently has a marketed National Class I new drug - Sulin, as well as multiple under-development National Class I new drugs and innovative traditional Chinese medicine drugs, including KC1036, CX1026, and CX1003. It has established a product pipeline covering multiple new drug varieties, addressing disease areas such as blood coagulation, orthopedics, and anti-tumor.
Qualifications and Honors
Kangchen Pharmaceutical is committed to new drug innovation: insisting on original R&D, emphasizing novelty and specialty, and pursuing excellence. It has obtained 56 domestic and international invention patents, undertaken and completed projects such as the "National 863 Program," "National Torch Program," "National Major New Drug Innovation (11th, 12th, and 13th Five-Year Plans)," and "National High-Tech Industrialization Demonstration Project." It has received honors including "National Intellectual Property Demonstration Enterprise" and "China Patent Excellence Award," accumulating strong core competitiveness in innovative drug R&D. The company has been awarded the "2022 China Top 100 Innovative Pharmaceutical Enterprises" and has been listed among the top 100 for many consecutive years.
R&D Strength
As a local Chinese innovative drug R&D enterprise, Kangchen Pharmaceutical has accumulated extensive experience in innovative drug R&D through practical experience. It has a mature drug research institute of nearly 5,000 square meters. Equipped with over 60 sets of various instruments, including ion chromatographs, gas chromatographs, high-performance liquid chromatographs, analytical flow cytometers, liquid chromatography-mass spectrometry systems, high-pressure preparative liquid chromatographs, tablet presses, wet granulators, granulation line - experimental fluid bed coater (Solidlab 2 Huttlin), cell reactors, AKTA, intelligent dissolution testers, stability sample chambers (constant temperature and humidity chambers), liquid chromatography evaporative light scattering detectors, preparative liquid chromatographs, and binocular microscopes, most drug R&D experiments can be completed internally.
Postdoctoral Research Workstation
The company has an N-level postdoctoral research workstation, with multiple postdoctoral researchers receiving various awards and funding. The company's postdoctoral training has formed a high-end cooperative mentor team including the chairman, dean/deputy dean, expert consultants, and global leading talents. The mentor team has received numerous honors: experts enjoying the Special Government Allowance of the State Council, National March 8th Red Banner Pacesetters, Beijing Model Workers, Beijing Outstanding Contributors in Science, Technology, and Management, Beijing Thousands of Talents, recipients of the Ministry of Science and Technology's "12th Five-Year Major New Drug Innovation" special funding, Beijing Hai Ju Project, Beijing Special Experts, Beijing Professor-level Senior Engineers, National Education Commission Science and Technology Progress Second Prize, and Sichuan Province* Special Experts.
Talent Structure
The company has established a complete R&D system and platform and cultivated a mature and steady R&D team with international standards, providing strong support for Kangchen Pharmaceutical's new drug innovation and continuous success. The proportion of employees with master's degrees or above is no less than 25%, with high talent density, effectively supporting the entire process from topic selection research, product screening, preclinical research, clinical research, registration application, industrialization transformation, to post-marketing clinical re-evaluation.
Compensation and Benefits
The company provides employees with a "four-in-one" compensation and benefits system, including competitive fixed salary, performance-based salary linked to assessment results, project rewards and long-term incentives linked to performance contributions, as well as comprehensive social insurance and housing fund and welfare subsidies, along with new employee training camps, cultural boot camps, running clubs, and other colorful employee activities.